TerminatedPhase 1/2

Apremilast in the Treatment of Uveitis

Stopped: Investigator discretion due to lack of efficacy in three subjects enrolled

United States3 participantsStarted 2009-11

Plain-language summary

The purpose of this study is to assess the safety and efficacy of Apremilast in the treatment of uveitis.

Who can participate

Age range

18 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * patients with vision-threatening autoimmune uveitis * failure to respond to prednisone and at least one other systemic immunosuppressive, or intolerance to such medications due to side effects Exclusion Criteria: * serious concomitant illness that could interfere with the subject's participation * previous or current use of an alkylating agent * use of CYP3A4 inhibitors during the trial * TNF blocker use within the 8 weeks prior to enrollment

Questions worth asking your doctor

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.

Questions for the trial coordinator

The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.

1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?

A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.

What they're measuring

Improvement by 2 or More Lines of Best-corrected Snellen Visual Acuity in at Least One Eye

Timeframe: 6 months

Reduction in Dose of Systemic Corticosteroid or Other Immunosuppressive Therapy by at Least 50%

Timeframe: 6 months

Control of Ocular Inflammation, as Judged on Clinical Criteria, According to Standard Methods (Reduction of Anterior Chamber Cellular Activity and/or Chorioretinal Infiltrates and/or Retinal Vasculitis)

Timeframe: 6 months

Reduction in Cystoid Macular Edema

Timeframe: 6 months

Trial details

NCT IDNCT00889421

SponsorOregon Health and Science University

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2011-06

Results submitted2014-06-06

View on ClinicalTrials.gov More Uveitis trials

Who can participate

Age range

18 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

What they're measuring

Improvement by 2 or More Lines of Best-corrected Snellen Visual Acuity in at Least One Eye

Timeframe: 6 months

Reduction in Dose of Systemic Corticosteroid or Other Immunosuppressive Therapy by at Least 50%

Timeframe: 6 months

Reduction in Cystoid Macular Edema

Timeframe: 6 months